Selected research
Industry Research
Biomolecule Software Industry Research Report 2026
Market perspective
The global Biomolecule Software market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Biomolecule Software market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Biomolecule Software market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Biomolecule Software market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Biomolecule Software include Hamilton Thorne, Hermes Medical Solutions, Inc, INDICAL BIOSCIENCE, lexogen, Repligen, SCC SOFT COMPUTER, Oxford Instruments, Partek, Inc. and Stilla Technologies, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Biomolecule Software market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Biomolecule Software.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biomolecule Software Market by Company
Hamilton Thorne
Hermes Medical Solutions, Inc
INDICAL BIOSCIENCE
lexogen
Repligen
SCC SOFT COMPUTER
Oxford Instruments
Partek, Inc.
Stilla Technologies
Vela Diagnostics
Vittoriobasurto
SCIEX
SoftGenetics, LLC.
Benchling
BioSistemika
CapitalBio Technology
cytena GmbH
Eppendorf SE
GenomSys
Mission Bio
Multid Analyses AB
PhenoSystems SA
Progenie Molecular
Biomolecule Software Segment by Type
Windows
Linux
MacOS
Biomolecule Software Segment by Application
Hospital
Clinic
Research Center
Biomolecule Software Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biomolecule Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biomolecule Software and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biomolecule Software.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biomolecule Software companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Windows
- Linux
- MacOS
Applications
- Hospital
- Clinic
- Research Center
Companies covered
- Hamilton Thorne
- Hermes Medical Solutions, Inc
- INDICAL BIOSCIENCE
- lexogen
- Repligen
- SCC SOFT COMPUTER
- Oxford Instruments
- Partek, Inc.
- Stilla Technologies
- Vela Diagnostics
- Vittoriobasurto
- SCIEX
- SoftGenetics, LLC.
- Benchling
- BioSistemika
- CapitalBio Technology
- cytena GmbH
- Eppendorf SE
- GenomSys
- Mission Bio
- Multid Analyses AB
- PhenoSystems SA
- Progenie Molecular
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Biomolecule Software by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Windows
- 2.2.3 Linux
- 2.2.4 MacOS
- 2.3 Biomolecule Software by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Research Center
- 2.4 Assumptions and Limitations
3 Biomolecule Software Breakdown Data by Type
- 3.1 Global Biomolecule Software Historic Market Size by Type (2021-2026)
- 3.2 Global Biomolecule Software Forecasted Market Size by Type (2027-2032)
4 Biomolecule Software Breakdown Data by Application
- 4.1 Global Biomolecule Software Historic Market Size by Application (2021-2026)
- 4.2 Global Biomolecule Software Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Biomolecule Software Market Perspective (2021-2032)
- 5.2 Global Biomolecule Software Growth Trends by Region
- 5.2.1 Global Biomolecule Software Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Biomolecule Software Historic Market Size by Region (2021-2026)
- 5.2.3 Biomolecule Software Forecasted Market Size by Region (2027-2032)
- 5.3 Biomolecule Software Market Dynamics
- 5.3.1 Biomolecule Software Industry Trends
- 5.3.2 Biomolecule Software Market Drivers
- 5.3.3 Biomolecule Software Market Challenges
- 5.3.4 Biomolecule Software Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Biomolecule Software Players by Revenue
- 6.1.1 Global Top Biomolecule Software Players by Revenue (2021-2026)
- 6.1.2 Global Biomolecule Software Revenue Market Share by Players (2021-2026)
- 6.2 Global Biomolecule Software Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Biomolecule Software Head Office and Area Served
- 6.4 Global Biomolecule Software Players, Product Type & Application
- 6.5 Global Biomolecule Software Manufacturers Established Date
- 6.6 Global Biomolecule Software Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Biomolecule Software Market Size (2021-2032)
- 7.2 North America Biomolecule Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Biomolecule Software Market Size by Country (2021-2026)
- 7.4 North America Biomolecule Software Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Biomolecule Software Market Size (2021-2032)
- 8.2 Europe Biomolecule Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Biomolecule Software Market Size by Country (2021-2026)
- 8.4 Europe Biomolecule Software Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Biomolecule Software Market Size (2021-2032)
- 9.2 Asia-Pacific Biomolecule Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Biomolecule Software Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Biomolecule Software Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Biomolecule Software Market Size (2021-2032)
- 10.2 South America Biomolecule Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Biomolecule Software Market Size by Country (2021-2026)
- 10.4 South America Biomolecule Software Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Biomolecule Software Market Size (2021-2032)
- 11.2 Middle East & Africa Biomolecule Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Biomolecule Software Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Biomolecule Software Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Hamilton Thorne
- 12.1.1 Hamilton Thorne Company Information
- 12.1.2 Hamilton Thorne Business Overview
- 12.1.3 Hamilton Thorne Revenue in Biomolecule Software Business (2021-2026)
- 12.1.4 Hamilton Thorne Biomolecule Software Product Portfolio
- 12.1.5 Hamilton Thorne Recent Developments
- 12.2 Hermes Medical Solutions, Inc
- 12.2.1 Hermes Medical Solutions, Inc Company Information
- 12.2.2 Hermes Medical Solutions, Inc Business Overview
- 12.2.3 Hermes Medical Solutions, Inc Revenue in Biomolecule Software Business (2021-2026)
- 12.2.4 Hermes Medical Solutions, Inc Biomolecule Software Product Portfolio
- 12.2.5 Hermes Medical Solutions, Inc Recent Developments
- 12.3 INDICAL BIOSCIENCE
- 12.3.1 INDICAL BIOSCIENCE Company Information
- 12.3.2 INDICAL BIOSCIENCE Business Overview
- 12.3.3 INDICAL BIOSCIENCE Revenue in Biomolecule Software Business (2021-2026)
- 12.3.4 INDICAL BIOSCIENCE Biomolecule Software Product Portfolio
- 12.3.5 INDICAL BIOSCIENCE Recent Developments
- 12.4 lexogen
- 12.4.1 lexogen Company Information
- 12.4.2 lexogen Business Overview
- 12.4.3 lexogen Revenue in Biomolecule Software Business (2021-2026)
- 12.4.4 lexogen Biomolecule Software Product Portfolio
- 12.4.5 lexogen Recent Developments
- 12.5 Repligen
- 12.5.1 Repligen Company Information
- 12.5.2 Repligen Business Overview
- 12.5.3 Repligen Revenue in Biomolecule Software Business (2021-2026)
- 12.5.4 Repligen Biomolecule Software Product Portfolio
- 12.5.5 Repligen Recent Developments
- 12.6 SCC SOFT COMPUTER
- 12.6.1 SCC SOFT COMPUTER Company Information
- 12.6.2 SCC SOFT COMPUTER Business Overview
- 12.6.3 SCC SOFT COMPUTER Revenue in Biomolecule Software Business (2021-2026)
- 12.6.4 SCC SOFT COMPUTER Biomolecule Software Product Portfolio
- 12.6.5 SCC SOFT COMPUTER Recent Developments
- 12.7 Oxford Instruments
- 12.7.1 Oxford Instruments Company Information
- 12.7.2 Oxford Instruments Business Overview
- 12.7.3 Oxford Instruments Revenue in Biomolecule Software Business (2021-2026)
- 12.7.4 Oxford Instruments Biomolecule Software Product Portfolio
- 12.7.5 Oxford Instruments Recent Developments
- 12.8 Partek, Inc.
- 12.8.1 Partek, Inc. Company Information
- 12.8.2 Partek, Inc. Business Overview
- 12.8.3 Partek, Inc. Revenue in Biomolecule Software Business (2021-2026)
- 12.8.4 Partek, Inc. Biomolecule Software Product Portfolio
- 12.8.5 Partek, Inc. Recent Developments
- 12.9 Stilla Technologies
- 12.9.1 Stilla Technologies Company Information
- 12.9.2 Stilla Technologies Business Overview
- 12.9.3 Stilla Technologies Revenue in Biomolecule Software Business (2021-2026)
- 12.9.4 Stilla Technologies Biomolecule Software Product Portfolio
- 12.9.5 Stilla Technologies Recent Developments
- 12.10 Vela Diagnostics
- 12.10.1 Vela Diagnostics Company Information
- 12.10.2 Vela Diagnostics Business Overview
- 12.10.3 Vela Diagnostics Revenue in Biomolecule Software Business (2021-2026)
- 12.10.4 Vela Diagnostics Biomolecule Software Product Portfolio
- 12.10.5 Vela Diagnostics Recent Developments
- 12.11 Vittoriobasurto
- 12.11.1 Vittoriobasurto Company Information
- 12.11.2 Vittoriobasurto Business Overview
- 12.11.3 Vittoriobasurto Revenue in Biomolecule Software Business (2021-2026)
- 12.11.4 Vittoriobasurto Biomolecule Software Product Portfolio
- 12.11.5 Vittoriobasurto Recent Developments
- 12.12 SCIEX
- 12.12.1 SCIEX Company Information
- 12.12.2 SCIEX Business Overview
- 12.12.3 SCIEX Revenue in Biomolecule Software Business (2021-2026)
- 12.12.4 SCIEX Biomolecule Software Product Portfolio
- 12.12.5 SCIEX Recent Developments
- 12.13 SoftGenetics, LLC.
- 12.13.1 SoftGenetics, LLC. Company Information
- 12.13.2 SoftGenetics, LLC. Business Overview
- 12.13.3 SoftGenetics, LLC. Revenue in Biomolecule Software Business (2021-2026)
- 12.13.4 SoftGenetics, LLC. Biomolecule Software Product Portfolio
- 12.13.5 SoftGenetics, LLC. Recent Developments
- 12.14 Benchling
- 12.14.1 Benchling Company Information
- 12.14.2 Benchling Business Overview
- 12.14.3 Benchling Revenue in Biomolecule Software Business (2021-2026)
- 12.14.4 Benchling Biomolecule Software Product Portfolio
- 12.14.5 Benchling Recent Developments
- 12.15 BioSistemika
- 12.15.1 BioSistemika Company Information
- 12.15.2 BioSistemika Business Overview
- 12.15.3 BioSistemika Revenue in Biomolecule Software Business (2021-2026)
- 12.15.4 BioSistemika Biomolecule Software Product Portfolio
- 12.15.5 BioSistemika Recent Developments
- 12.16 CapitalBio Technology
- 12.16.1 CapitalBio Technology Company Information
- 12.16.2 CapitalBio Technology Business Overview
- 12.16.3 CapitalBio Technology Revenue in Biomolecule Software Business (2021-2026)
- 12.16.4 CapitalBio Technology Biomolecule Software Product Portfolio
- 12.16.5 CapitalBio Technology Recent Developments
- 12.17 cytena GmbH
- 12.17.1 cytena GmbH Company Information
- 12.17.2 cytena GmbH Business Overview
- 12.17.3 cytena GmbH Revenue in Biomolecule Software Business (2021-2026)
- 12.17.4 cytena GmbH Biomolecule Software Product Portfolio
- 12.17.5 cytena GmbH Recent Developments
- 12.18 Eppendorf SE
- 12.18.1 Eppendorf SE Company Information
- 12.18.2 Eppendorf SE Business Overview
- 12.18.3 Eppendorf SE Revenue in Biomolecule Software Business (2021-2026)
- 12.18.4 Eppendorf SE Biomolecule Software Product Portfolio
- 12.18.5 Eppendorf SE Recent Developments
- 12.19 GenomSys
- 12.19.1 GenomSys Company Information
- 12.19.2 GenomSys Business Overview
- 12.19.3 GenomSys Revenue in Biomolecule Software Business (2021-2026)
- 12.19.4 GenomSys Biomolecule Software Product Portfolio
- 12.19.5 GenomSys Recent Developments
- 12.20 Mission Bio
- 12.20.1 Mission Bio Company Information
- 12.20.2 Mission Bio Business Overview
- 12.20.3 Mission Bio Revenue in Biomolecule Software Business (2021-2026)
- 12.20.4 Mission Bio Biomolecule Software Product Portfolio
- 12.20.5 Mission Bio Recent Developments
- 12.21 Multid Analyses AB
- 12.21.1 Multid Analyses AB Company Information
- 12.21.2 Multid Analyses AB Business Overview
- 12.21.3 Multid Analyses AB Revenue in Biomolecule Software Business (2021-2026)
- 12.21.4 Multid Analyses AB Biomolecule Software Product Portfolio
- 12.21.5 Multid Analyses AB Recent Developments
- 12.22 PhenoSystems SA
- 12.22.1 PhenoSystems SA Company Information
- 12.22.2 PhenoSystems SA Business Overview
- 12.22.3 PhenoSystems SA Revenue in Biomolecule Software Business (2021-2026)
- 12.22.4 PhenoSystems SA Biomolecule Software Product Portfolio
- 12.22.5 PhenoSystems SA Recent Developments
- 12.23 Progenie Molecular
- 12.23.1 Progenie Molecular Company Information
- 12.23.2 Progenie Molecular Business Overview
- 12.23.3 Progenie Molecular Revenue in Biomolecule Software Business (2021-2026)
- 12.23.4 Progenie Molecular Biomolecule Software Product Portfolio
- 12.23.5 Progenie Molecular Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst